340 related articles for article (PubMed ID: 26890830)
1. Safety and technique of ferumoxytol administration for MRI.
Vasanawala SS; Nguyen KL; Hope MD; Bridges MD; Hope TA; Reeder SB; Bashir MR
Magn Reson Med; 2016 May; 75(5):2107-11. PubMed ID: 26890830
[TBL] [Abstract][Full Text] [Related]
2. Imaging Tumor Necrosis with Ferumoxytol.
Aghighi M; Golovko D; Ansari C; Marina NM; Pisani L; Kurlander L; Klenk C; Bhaumik S; Wendland M; Daldrup-Link HE
PLoS One; 2015; 10(11):e0142665. PubMed ID: 26569397
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of islet magnetic resonance imaging using ferumoxytol in intraportal islet transplantation.
Jin SM; Oh SH; Oh BJ; Shim W; Choi JM; Yoo D; Hwang YH; Lee JH; Lee DY; Kim JH
Biomaterials; 2015 Jun; 52():272-80. PubMed ID: 25818433
[TBL] [Abstract][Full Text] [Related]
4. Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: Comparison to standard of care.
Varallyay CG; Nesbit E; Horvath A; Varallyay P; Fu R; Gahramanov S; Muldoon LL; Li X; Rooney WD; Neuwelt EA
J Magn Reson Imaging; 2018 Aug; 48(2):441-448. PubMed ID: 29314418
[TBL] [Abstract][Full Text] [Related]
5. Ferumoxytol: a new era of iron deficiency anemia treatment for patients with chronic kidney disease.
Kowalczyk M; Banach M; Rysz J
J Nephrol; 2011; 24(6):717-22. PubMed ID: 21956770
[TBL] [Abstract][Full Text] [Related]
6. Macrophage uptake switches on OCT contrast of superparamagnetic nanoparticles for imaging of atherosclerotic plaques.
Ariza de Schellenberger A; Poller WC; Stangl V; Landmesser U; Schellenberger E
Int J Nanomedicine; 2018; 13():7905-7913. PubMed ID: 30538467
[TBL] [Abstract][Full Text] [Related]
7. Emerging applications for ferumoxytol as a contrast agent in MRI.
Bashir MR; Bhatti L; Marin D; Nelson RC
J Magn Reson Imaging; 2015 Apr; 41(4):884-98. PubMed ID: 24974785
[TBL] [Abstract][Full Text] [Related]
8. Safety of ferumoxytol in children undergoing cardiac MRI under general anaesthesia.
Wise-Faberowski L; Velasquez N; Chan F; Vasanawala S; McElhinney DB; Ramamoorthy C
Cardiol Young; 2018 Jul; 28(7):916-921. PubMed ID: 29848399
[TBL] [Abstract][Full Text] [Related]
9. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study.
Neuwelt EA; Várallyay CG; Manninger S; Solymosi D; Haluska M; Hunt MA; Nesbit G; Stevens A; Jerosch-Herold M; Jacobs PM; Hoffman JM
Neurosurgery; 2007 Apr; 60(4):601-11; discussion 611-2. PubMed ID: 17415196
[TBL] [Abstract][Full Text] [Related]
10. Hemodynamic safety and efficacy of ferumoxytol as an intravenous contrast agents in pediatric patients and young adults.
Ning P; Zucker EJ; Wong P; Vasanawala SS
Magn Reson Imaging; 2016 Feb; 34(2):152-8. PubMed ID: 26518061
[TBL] [Abstract][Full Text] [Related]
11. Differential uptake of ferumoxtran-10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: critical determinants of atherosclerotic plaque labeling.
Yancy AD; Olzinski AR; Hu TC; Lenhard SC; Aravindhan K; Gruver SM; Jacobs PM; Willette RN; Jucker BM
J Magn Reson Imaging; 2005 Apr; 21(4):432-42. PubMed ID: 15779033
[TBL] [Abstract][Full Text] [Related]
12. Brain iron deposition after Ferumoxytol-enhanced MRI: A study of Porcine Brains.
Theruvath AJ; Aghighi M; Iv M; Nejadnik H; Lavezo J; Pisani LJ; Daldrup-Link HE
Nanotheranostics; 2020; 4(4):195-200. PubMed ID: 32637297
[TBL] [Abstract][Full Text] [Related]
13. Ferumoxytol use as an intravenous contrast agent for magnetic resonance angiography.
Stabi KL; Bendz LM
Ann Pharmacother; 2011 Dec; 45(12):1571-5. PubMed ID: 22045905
[TBL] [Abstract][Full Text] [Related]
14. Macrophage Imaging of Cerebral Aneurysms with Ferumoxytol: an Exploratory Study in an Animal Model and in Patients.
Aoki T; Saito M; Koseki H; Tsuji K; Tsuji A; Murata K; Kasuya H; Morita A; Narumiya S; Nozaki K;
J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2055-2064. PubMed ID: 28774792
[TBL] [Abstract][Full Text] [Related]
15. Ferumoxytol-Enhanced Magnetic Resonance Imaging in Late-Stage CKD.
Mukundan S; Steigner ML; Hsiao LL; Malek SK; Tullius SG; Chin MS; Siedlecki AM
Am J Kidney Dis; 2016 Jun; 67(6):984-8. PubMed ID: 26786296
[TBL] [Abstract][Full Text] [Related]
16. Clinical applications of iron oxide nanoparticles for magnetic resonance imaging of brain tumors.
Iv M; Telischak N; Feng D; Holdsworth SJ; Yeom KW; Daldrup-Link HE
Nanomedicine (Lond); 2015; 10(6):993-1018. PubMed ID: 25867862
[TBL] [Abstract][Full Text] [Related]
17. A comparison of ferumoxytol with gadolinium as contrast agents for the diagnostic magnetic resonance imaging of osteomyelitis.
Langsjoen J; Neuwelt A; Eberhardt S; Mlady G; Shukla U; Murali S; Pizanis C; Sillerud LO
Magn Reson Imaging; 2020 Sep; 71():45-54. PubMed ID: 32439428
[TBL] [Abstract][Full Text] [Related]
18. Multicenter Safety and Practice for Off-Label Diagnostic Use of Ferumoxytol in MRI.
Nguyen KL; Yoshida T; Kathuria-Prakash N; Zaki IH; Varallyay CG; Semple SI; Saouaf R; Rigsby CK; Stoumpos S; Whitehead KK; Griffin LM; Saloner D; Hope MD; Prince MR; Fogel MA; Schiebler ML; Roditi GH; Radjenovic A; Newby DE; Neuwelt EA; Bashir MR; Hu P; Finn JP
Radiology; 2019 Dec; 293(3):554-564. PubMed ID: 31638489
[TBL] [Abstract][Full Text] [Related]
19. Safety of Off-Label Use of Ferumoxtyol as a Contrast Agent for MRI: A Systematic Review and Meta-Analysis of Adverse Events.
Ahmad F; Treanor L; McGrath TA; Walker D; McInnes MDF; Schieda N
J Magn Reson Imaging; 2021 Mar; 53(3):840-858. PubMed ID: 33098154
[TBL] [Abstract][Full Text] [Related]
20. Ferumoxytol administration does not alter infarct volume or the inflammatory response to stroke in mice.
Doyle KP; Quach LN; Arceuil HE; Buckwalter MS
Neurosci Lett; 2015 Jan; 584():236-40. PubMed ID: 25449870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
